ECSP055849A - Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico - Google Patents

Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Info

Publication number
ECSP055849A
ECSP055849A EC2005005849A ECSP055849A ECSP055849A EC SP055849 A ECSP055849 A EC SP055849A EC 2005005849 A EC2005005849 A EC 2005005849A EC SP055849 A ECSP055849 A EC SP055849A EC SP055849 A ECSP055849 A EC SP055849A
Authority
EC
Ecuador
Prior art keywords
human
binding molecule
nogo
antibody
pharmaceutical use
Prior art date
Application number
EC2005005849A
Other languages
English (en)
Inventor
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schenell
Martin E Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of ECSP055849A publication Critical patent/ECSP055849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invención se refiere a moléculas, tales como, por ejemplo, anticuerpos monoclonales o fragmentos Fab de los mismos, los cuales son capaces de enlazarse con el polipéptido NogoA humano, o NiG humano, o NiG-D20 humano, o NogoA_623-640 humano, con una constante de disociación < 1000 nM; polinucleótidos que codifican esta molécula de enlace; un vector de expresión que comprende estos polinucleótidos; el uso de esta molécula de enlace en el tratamiento de reparación de nervios; una composición farmacéutica que comprende dicha molécula de enlace; y a un método de tratamiento de enfermedades asociadas con la reparación de nervios.
EC2005005849A 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico ECSP055849A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound

Publications (1)

Publication Number Publication Date
ECSP055849A true ECSP055849A (es) 2005-09-20

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005849A ECSP055849A (es) 2002-12-10 2005-06-10 Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico

Country Status (24)

Country Link
US (2) US7785593B2 (es)
EP (1) EP1572745B1 (es)
JP (1) JP4504200B2 (es)
KR (1) KR101215801B1 (es)
CN (1) CN100384877C (es)
AT (1) ATE475671T1 (es)
AU (1) AU2003289998B2 (es)
BR (1) BR0317161A (es)
CA (1) CA2509068C (es)
CY (1) CY1110848T1 (es)
DE (1) DE60333585D1 (es)
DK (1) DK1572745T3 (es)
EC (1) ECSP055849A (es)
ES (1) ES2349293T3 (es)
GB (1) GB0228832D0 (es)
IL (1) IL169018A (es)
MX (1) MXPA05006265A (es)
NO (1) NO20053304L (es)
PL (1) PL210720B1 (es)
PT (1) PT1572745E (es)
RU (1) RU2350623C2 (es)
SI (1) SI1572745T1 (es)
WO (1) WO2004052932A2 (es)
ZA (1) ZA200504522B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) * 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
WO2007003421A2 (en) * 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5698534B2 (ja) * 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
EP3007556B1 (en) * 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
CN109071666B (zh) 2016-03-01 2022-06-28 耶路撒冷希伯来大学伊森姆研究发展有限公司 人脊髓灰质炎病毒受体(pvr)特异性抗体
JP7754506B2 (ja) 2019-10-08 2025-10-15 ネクチン セラピューティクス エルティーディー． ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
MX2022004737A (es) * 2019-10-24 2023-02-16 Novago Therapeutics Ag Anticuerpos anti-nogo-a novedosos.
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
KR100728405B1 (ko) 1998-11-06 2007-06-13 더 유니버시티 오브 취리히 Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
CU22921A1 (es) * 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
ES2341842T3 (es) * 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
EP2165714B1 (en) * 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
DK1461300T3 (da) * 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DK1711530T3 (da) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
US20060183678A1 (en) 2006-08-17
ATE475671T1 (de) 2010-08-15
IL169018A (en) 2012-07-31
ZA200504522B (en) 2006-03-29
US20110059110A1 (en) 2011-03-10
AU2003289998A1 (en) 2004-06-30
WO2004052932A3 (en) 2004-10-21
KR20050095768A (ko) 2005-09-30
NO20053304D0 (no) 2005-07-06
PL377506A1 (pl) 2006-02-06
MXPA05006265A (es) 2005-12-05
EP1572745A2 (en) 2005-09-14
JP2006523087A (ja) 2006-10-12
US8535666B2 (en) 2013-09-17
EP1572745B1 (en) 2010-07-28
DE60333585D1 (de) 2010-09-09
ES2349293T3 (es) 2010-12-29
JP4504200B2 (ja) 2010-07-14
CY1110848T1 (el) 2015-06-10
HK1084676A1 (en) 2006-08-04
RU2005121669A (ru) 2007-01-20
PL210720B1 (pl) 2012-02-29
SI1572745T1 (sl) 2010-12-31
US7785593B2 (en) 2010-08-31
KR101215801B1 (ko) 2012-12-26
RU2350623C2 (ru) 2009-03-27
CN1747971A (zh) 2006-03-15
BR0317161A (pt) 2005-11-01
GB0228832D0 (en) 2003-01-15
WO2004052932A2 (en) 2004-06-24
CA2509068C (en) 2012-02-07
NO20053304L (no) 2005-09-07
CA2509068A1 (en) 2004-06-24
AU2003289998B2 (en) 2008-02-14
CN100384877C (zh) 2008-04-30
DK1572745T3 (da) 2010-10-25
PT1572745E (pt) 2010-10-21

Similar Documents

Publication Publication Date Title
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
Pisarewicz et al. Polypeptide chains containing d-γ-hydroxyvaline
BG111652A (en) Antibodies against the receptor of insulin-like growth factor i
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700136A1 (ru) Анти-cd154-антитела
ATE382053T1 (de) System zur antikörperexpression und- synthese
CA2256308A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
MX2009013955A (es) Dominios de union de proteina morfogenica osea (bmp) de proteinas de la familia de proteina de molecula repulsiva de la direccion (rgm) y sus fragmentos funcionales, y su uso.
WO2006087637A3 (en) Anti her2/neu antibody
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
Liu et al. Effect of the light chain C-terminal serine residue on disulfide bond susceptibility of human immunoglobulin G1λ
ATE401402T1 (de) Mit syndekan interagierende proteine und deren verwendung
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания